ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
Providing a VOICE for Colorado's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1991
Meetings & Education
Allied Health Professionals Award
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
RMOS Corporate Members
Become a Corporate Member
Industry News Archives
COVID-19 Featured Resources
FDA Approves Atezolizumab Plus Nab-paclitaxel for TNBC
On March 8, the FDA approved atezolizumab (Tecentriq, Genentech Inc.) plus nab-paclitaxel (Abraxane, Celgene) for the frontline treatment of patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer (TNBC).
Read OncLive news coverage here